Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Mallinckrodt Stock (NYSE:MNK) 30 days 90 days 365 days Advanced Chart Get Mallinckrodt alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.14▼$0.7552-Week Range N/AVolume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More… Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address MNK Stock News HeadlinesRobbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Mallinckrodt Securities LitigationJanuary 20, 2025 | businesswire.comMallinckrodt Completes Divestiture of Therakos® BusinessDecember 2, 2024 | finance.yahoo.comWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary investor who picked Nvidia before shares exploded as high as 3,423%... Before April 30th, President Trump could make a shocking AI announcement...February 22, 2025 | InvestorPlace (Ad)Mallinckrodt to Present at Jefferies London Healthcare ConferenceNovember 15, 2024 | uk.finance.yahoo.comMallinckrodt to Report Earnings Results for Third Quarter 2024October 24, 2024 | finance.yahoo.comHudson Bay Capital Management LP Acquires New Stake in Mallinckrodt PLCOctober 22, 2024 | finance.yahoo.comMallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. HospitalsOctober 10, 2024 | finance.yahoo.comMallinckrodt plc: THERAKOS CELLEX Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)September 3, 2024 | finanznachrichten.deSee More Headlines MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) released its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.55. The company's revenue for the quarter was down 14.9% compared to the same quarter last year. Read the conference call transcript. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mallinckrodt investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Endo International (ENDP), Bausch Health Companies (BHC), Meta Platforms (META) and Gerdau (GGB). Company Calendar Last Earnings8/04/2020Today2/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / BookN/AMiscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NYSE:MNK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mallinckrodt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.